human thyrotropin beta

Human thyrotropin beta (Zesuning) is a recombinant human thyroid-stimulating hormone (rhTSH) developed by Zelgen for the postoperative management and diagnostic assessment of patients with differentiated thyroid cancer (DTC). Structurally identical to endogenous human TSH, it binds to and activates the thyroid-stimulating hormone receptor (TSHR) on thyroid cells and DTC cells. This activation stimulates iodine uptake and the synthesis and secretion of thyroglobulin (Tg) without requiring patients to undergo thyroid hormone withdrawal, thereby avoiding the debilitating symptoms of hypothyroidism. Zesuning was approved in China in January 2026 as an adjunctive diagnostic tool for serum Tg testing and radioiodine whole-body scanning (WBS) in postoperative DTC follow-up, and is being commercialized in partnership with Merck KGaA. It is also in Phase III development for thyroid remnant ablation.